Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry.

In the PS-matched cohort, a similar trend favoring auto-SCT was observed, although differences did not reach statistical significance: median RFS was 62.78 vs. 34.86 months (HR 0.66, p = 0.150), and median OS was not reached vs. 75.85 months (HR 0.57, p = 0.125).

also in 111,027 other papers